Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
3
P 104
3D PRINTED CUTTING GUIDES FOR LONG BONE SARCOMA RESECTION AND INTERCALARY ALLOGRAFT RECONSTRUCTION: A CASE SERIES
Favorite
A
P 188
A CALCULATOR TO ESTIMATE EFFECTIVE IMATINIB CONCENTRATIONS IN GIST AFTER ADJUSTING FOR PROTEIN BINDING
Favorite
P 160
A COMPARATIVE ANALYSIS OF DEDIFFERENTIATED AND CONVENTIONAL CHONDROSARCOMA OUTCOMES
Favorite
P 91
A COMPARISON OF ACETABULAR AUGMENTATION AND PHOTODYNAMIC NAIL STABILIZATION FOR COMPLEX ONCOLOGIC TOTAL HIP ARTHROPLASTY
Favorite
P 116
A DUAL-TARGETED SYSTEMIC THERAPEUTIC APPROACH FOR THE SELECTIVE ELIMINATION OF TUMOR CELLS IN PRIMARY AND METASTATIC SARCOMA.
Favorite
P 434
A FIRST-IN-HUMAN PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
P 311
A FOLLOW-UP STUDY ON THE NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING FOR EXTREMITY DESMOID FIBROMATOSIS RESPONSE ASSESSMENT
Favorite
P 07
A LIVING MULTI-OMICS BIOBANK OF PATIENT-DERIVED XENOGRAFT MODELS FOR SARCOMA
Favorite
P 84
A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS
Favorite
P 138
A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION
Favorite
P 50
A NEW MURINE MODEL OF DEDIFFERENTIATED LIPOSARCOMA DEFINED BY HIGH PROLIFERATION AND METABOLIC ADAPTABILITY
Favorite
P 430
A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS
Favorite
P 287
A PHASE 1 STUDY OF NEOADJUVANT CABOZANTINIB IN COMBINATION WITH RADIATION THERAPY FOR SARCOMAS OF THE EXTREMITIES
Favorite
P 415
A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Favorite
P 416
A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
Favorite
P 426
A PHASE I/II TRIAL USING RNA LIPID NANOPARTICLES FOR RECURRENT OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Favorite
P 435
A PHASE II STUDY OF HIGH DOSE IFOSFAMIDE IN METASTATIC/LOCALLY ADVANCED SYNOVIAL SARCOMA FROM A TERTIARY CARE CENTER IN INDIA
Favorite
P 461
A RETROSPECTIVE ANALYSIS OF PATIENTS WITH CONVENTIONAL CHORDOMA TREATED WITH SYSTEMIC THERAPY
Favorite
P 141
A RETROSPECTIVE ANALYSIS OF THE BIRMINGHAM ATYPICAL CARTILAGE TUMOUR IMAGING PROTOCOL (BACTIP) IN MANAGING CENTRAL CARTILAGE TUMORS OF THE LONG BONES
Favorite
P 457
A RETROSPECTIVE REVIEW OF LOW-GRADE FIBROMYXOID SARCOMA: SURGICAL MANAGEMENT, RADIATION THERAPY, AND OUTCOMES
Favorite
P 44
A SYSTEMATIC REVIEW OF FUSION-DRIVEN SARCOMAS
Favorite
P 183
ACTIONABLE GENOMICS IN GASTROINTESTINAL STROMAL TUMORS LACKING KIT OR PDGFRA MUTATIONS.
Favorite
P 87
ACUTE PATHOLOGICAL LONG BONE FRACTURES: WEEKEND VERSUS WEEKDAY VARIATIONS AND THEIR CLINICAL IMPACT
Favorite
P 367
ADHERENCE TO GERMAN SARCOMA GUIDELINE FOR MRI SEQUENCING IN SOFT TISSUE SARCOMA: EVALUATION OF IMAGING PRACTICES AND COMPLIANCE
Favorite
P 28
ADVANCING PRECISION ONCOLOGY IN SOFT TISSUE SARCOMAS: THE ROLE OF ITRAC IN METASTATIC RISK STRATIFICATION AND TREATMENT PERSONALIZATION
Favorite
P 79
AGE-BASED TREATMENT PATTERNS AND OUTCOMES OF LOCALIZED HIGH-GRADE OSTEOSARCOMA FROM A NATIONWIDE DATABASE: WHAT IS THE OPTIMAL STRATEGY FOR PATIENTS OLDER THAN 40 YEARS?
Favorite
P 235
AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS
Favorite
P 96
AMPUTATION FOLLOWING MEGAPROSTHESIS USE IN LIMB SALVAGE
Favorite
P 189
AN ALGORITHM TO PERSONALIZE IMATINIB PLASMA TESTING AND DOSE DECISIONS IN GIST PATIENTS
Favorite
P 248
AN EX VIVO ASSAY TO PREDICT IMMUNOTHERAPY RESPONSE IN SARCOMA
Favorite
P 127
AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Favorite
P 314
AN INTERNATIONAL, MULTI-CENTRE STUDY OF SURGICAL MARGINS IN INTERMEDIATE TO HIGH GRADE SARCOMA
Favorite
P 439
AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
Favorite
P 424
AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Favorite
P 255
AN OPEN-LABEL, TWO-COHORT, PHASE 1A/B STUDY OF WEEKLY IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH VINCRISTINE AND TEMOZOLOMIDE (NALIRI-VT) IN PATIENTS WITH ADVANCED EWING SARCOMA
Favorite
P 315
ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Favorite
P 297
ANALYSIS OF CTDNA KINETICS IN PATIENTS WITH METASTATIC LEIOMYOSARCOMA UNDERGOING LOCOREGIONAL PROCEDURAL INTERVENTION
Favorite
P 204
ANALYSIS OF QUALITY INDICATORS OF SOFT TISSUE SARCOMA TREATMENT WITH CANCER REGISTRY DATA IN GERMANY 2015-2021
Favorite
P 29
ANTI-TUMOR ACTIVITY OF MICVOTABART PELIDOTIN IS ASSOCIATED WITH ENZYME GENE EXPRESSION IN PATIENT-DERIVED XENOGRAFT SARCOMA MODELS
Favorite
P 312
APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS
Favorite
P 142
ARE THERE INDEPENDENT PREDICTORS OF DEDIFFERENTIATED CHONDROSARCOMA ON MAGNETIC RESONANCE IMAGING? A MULTIVARIATE ANALYSIS
Favorite
P 316
AREA DEPRIVATION INDEX (ADI) AND OUTCOMES IN LOCALIZED SOFT TISSUE SARCOMA: DO SOCIAL DETERMINANTS INFLUENCE SURVIVAL?
Favorite
P 66
ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN: WHOLE TRANSCRIPTOME SEQUENCING ON SPATIALLY SEPARATED REGIONS, PATIENT-DERIVED MODELS, AND ORTHOTOPIC IN VIVO ANALYSIS
Favorite
P 81
ASSESSING PROGNOSTIC FACTORS OF CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH MALIGNANT GIANT CELL TUMORS: A POPULATION BASED STUDY FROM THE SEER DATABASE
Favorite
P 113
ASSESSING TREATMENT OUTCOMES OF CHONDROMYXOID FIBROMA: A CASE SERIES
Favorite
P 368
ASSESSMENT OF PAIN DIAGNOSIS AND PAIN MEDICATION USE IN ADULTS TREATED WITH NIROGACESTAT: A UNITED STATES REAL-WORLD ANALYSIS
Favorite
P 64
ATRX EXPRESSION CORRELATES WITH REDUCED IMMUNE CHECKPOINT EXPRESSION AND POOR SURVIVAL IN HIGH-RISK SOFT TISSUE SARCOMAS
Favorite
P 391
ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Favorite
P 310
ATYPICAL SPINDLE CELL PLEOMORPHIC LIPOMATOUS TUMORS OF THE RETROPERITONEUM ARE HETEROGENOUS: A REPORT OF FOUR DISPARATE CASES
Favorite
B
P 77
BARRIERS TO GUIDELINE CONCORDANT CARE IN AYA PATIENTS WITH BONE SARCOMAS
Favorite
P 154
BCOR-MUTATED CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA: A CLINICOPATHOLOGIC STUDY
Favorite
P 169
BENCHMARKING LARGE LANGUAGE MODELS VS MULTIDISCIPLINARY TUMOR BOARDS OF 21 SARCOMA CENTERS
Favorite
P 458
BETWEEN LYMPHOMAS AND SARCOMAS: A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG) ON HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN)
Favorite
P 425
BEZUCLASTINIB EXPANDED ACCESS PROGRAM (EAP) FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)
Favorite
P 174
BIAS OR BEST FIT? A COMPARATIVE ANALYSIS OF SEER AND NCDB DATASETS IN SINGLE MODEL MACHINE LEARNING FOR PREDICTING OSTEOSARCOMA SURVIVAL OUTCOMES
Favorite
P 186
BRAF V600E-MUTATED GASTROINTESTINAL STROMAL TUMORS: A CASE SERIES AND ANALYSIS OF IMMUNE TUMOR INFILTRATE
Favorite
P 155
BRCA2-MUTATED CONVENTIONAL CHONDROSARCOMA RESPONDING TO PARP INHIBITION: A CASE REPORT
Favorite
P 39
BUB1 AN OVEREXPRESSED KINASE IN SARCOMA: FINDING NEW TARGET THERAPY FOR OSTEOSARCOMA, LIPOSARCOMA, SYNOVIAL SARCOMA AND LEIOMYOSARCOMA
Favorite
P 08
BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Favorite
P 317
BUILDING A PRE-SURGICAL MULTIPARAMETRIC-MRI-BASED PREDICTIVE TREATMENT RESPONSE MODEL FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA TO REPLACE RECIST
Favorite
P 318
BURIED DE-EPITHELIALIZED FLAP RECONSTRUCTION AFTER WIDE EXCISION OF THIGH SARCOMAS: EARLY EXPERIENCE FROM A SPECIALIZED SARCOMA SURGERY UNIT
Favorite
C
P 185
CANCER TESTIS ANTIGENS AS TARGETS IN KIT11-MUTATED, IMATINIB-RESISTANT GIST
Favorite
P 86
CARBON FIBRE-REINFORCED PEEK IMPLANTS FOR TUMORS OF THE SPINE
Favorite
P 319
CARDIOTOXICITY AND OVERALL SURVIVAL IN PATIENTS WITH SARCOMA TREATED WITH DOXORUBICIN, OLARATUMAB AND DEXRAZOXANE: A REAL-WORLD EXPERIENCE IN DENMARK
Favorite
P 440
CASE REPORT: COMPLETE CLINICAL AND MOLECULAR RESPONSE TO INTRATUMORAL STX-001, AN LNP-SELF REPLICATING MRNA EXPRESSING IL-12 IN A PATIENT WITH REFRACTORY ANGIOSARCOMA
Favorite
P 75
CD248 AS A PROGNOSTIC MARKER IN OSTEOSARCOMA
Favorite
P 76
CD47 BLOCKADE SYNERGIZES WITH CHEMOTHERAPY IN ENHANCING MACROPHAGE PHAGOCYTOSIS OF EWING SARCOMA CELLS
Favorite
P 205
CENTRALIZATION OF SARCOMA CARE IMPROVES OUTCOMES DESPITE POORER PRESENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
P 148
CHARACTERISTICS AND OUTCOMES OF CHONDROSARCOMA PATIENTS TREATED WITH PROTON THERAPY: A SYSTEMATIC REVIEW OF PUBLISHED SERIES
Favorite
P 199
CHARACTERISTICS OF AN IMMUNOHISTOCHEMICAL AND MOLECULARLY DISCORDANT POPULATION OF GIST PATIENTS: A SINGLE CENTER RETROSPECTIVE REVIEW
Favorite
P 421
CHARACTERIZING THE IMMUNE RESPONSE TO INTRATUMORAL TIGILANOL TIGLATE (TT) IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS) IN A PHASE IIA TRIAL (NCT05755113)
Favorite
P 239
CHARACTERIZING THE ROLES OF T-CELLS IN THE CONTEXT OF TUMOR CLEARANCE AND MEMORY IN THE KP MODEL OF SARCOMA FOLLOWING STING THERAPY
Favorite
P 159
CHONDROSARCOMA IN JAPAN: A POPULATION-BASED ANALYSIS USING NATIONAL CANCER REGISTRY
Favorite
P 163
CHONDROSARCOMA IN THE AYA POPULATION
Favorite
P 156
CHONDROSARCOMA INCIDENCE, SURVIVAL AND MANAGEMENT IN ENGLAND 2013-2022; AN ANALYSIS FROM THE NATIONAL DISEASE REGISTRATION SERVICE
Favorite
P 162
CHONDROSARCOMA OUTCOMES IN YOUNG VERSUS ADULT POPULATIONS
Favorite
P 230
CIRCULATING TUMOR DNA AS AN EARLY INDICATOR OF RESPONSE, PROGRESSION, AND RECURRENCE OF SARCOMAS
Favorite
P 392
CLASSIFICATION AND DIFFERENTIATIONOF MYXOID LIPOSARCOMA AND MYXOMA WITH MACHINE LEARNING
Favorite
P 355
CLASSIFYING WOUND HEALING COMPLICATIONS IN SURGICALLY TREATED EXTREMITY SOFT TISSUE SARCOMA
Favorite
P 193
CLINICAL ANALYSIS OF RIPRETINIB DOSE ESCALATION IN ADVANCED GISTS AFTER STANDARD DOSE PROGRESSION
Favorite
P 369
CLINICAL CHARACTERISTICS & TREATMENT OUTCOME PATTERNS OF SOLITARY FIBROUS TUMORS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Favorite
P 320
CLINICAL CHARACTERISTICS AND RECURRENCE PATTERNS IN HISPANIC VS. NON-HISPANIC PATIENTS WITH LEIOMYOSARCOMA: FINDINGS FROM A RETROSPECTIVE SINGLE-CENTER COHORT STUDY
Favorite
P 161
CLINICAL CHARACTERISTICS, PATTERNS OF CARE, AND TREATMENT OUTCOMES OF CHONDROSARCOMA: A SINGLE-INSTITUTIONAL EXPERIENCE
Favorite
P 437
CLINICAL DATA CONFIRM GALENIC PRINCIPLE AND DEMONSTRATE THERAPEUTIC POTENTIAL OF THE001 (DPPG2-TSL-DOX) PLUS REGIONAL HYPERTHERMIA IN SOFT TISSUE SARCOMA
Favorite
P 290
CLINICAL OUTCOMES AFTER RADIOTHERAPY FOR PATIENTS WITH POORLY DIFFERENTIATED CHORDOMA
Favorite
P 370
CLINICAL OUTCOMES OF CUTANEOUS UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND SUBCUTANEOUS MYXOFIBROSARCOMA: A RETROSPECTIVE REVIEW
Favorite
P 371
CLINICAL PROFILE AND TREATMENT PATTERNS OF ANGIOSARCOMA IN THE REAL- WORLD SETTING: A SINGLE CENTER EXPERIENCE FROM 1991-2024.
Favorite
P 243
CLINICAL SIGNIFICANCE OF TUMOR-INFILTRATING IMMUNE CELL SUBSETS IN THE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS AND LEIOMYOSARCOMAS
Favorite
P 468
CLINICAL UTILITY OF TARGETED NEXT-GENERATION SEQUENCING IN GUIDING SARCOMA DIAGNOSIS AND PERSONALIZED MANAGEMENT: A SINGLE-CENTER STUDY FROM INDIA
Favorite
P 372
CLINICOPATHOLOGICAL FEATURES AND OUTCOMES OF PATIENTS WITH KAPOSI SARCOMA: A SINGLE CENTER RETROSPECTIVE REAL WORLD ANALYSIS
Favorite
P 10
COLLATERAL SENSITIVIES EMERGE DURING THE EVOLUTION OF CHEMORESISTANCE TO MAP CHEMOTHERAPY IN OSTEOSARCOMA
Favorite
P 441
COLOSARC-Q: A PROSPECTIVE MULTICENTER STUDY FOR EVALUATING SURGICAL STRATEGIES FOR COLORECTAL RESECTIONS AND POSTOPERATIVE QUALITY OF LIFE IN RETROPERITONEAL SARCOMA PATIENTS
Favorite
P 471
COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL: A HIGHLY EFFICACIOUS AND BETTER TOLERATED OPTION FOR ANGIOSARCOMA
Favorite
P 321
COMPARATIVE ANALYSIS OF FIRST-LINE DOXORUBICIN-BASED COMBINATION REGIMENS IN METASTATIC LEIOMYOSARCOMA: IMPACT ON SURVIVAL AND DISEASE CONTROL
Favorite
P 180
COMPARATIVE EFFICACY OF GENERIC AND BRAND-NAME IMATINIB IN NEOADJUVANT TREATMENT OF KIT EXON 11 MUTANT GIST
Favorite
P 95
COMPARATIVE OUTCOMES OF OPERATIVE AND NON-OPERATIVE TREATMENT FOR METASTATIC HUMERAL PATHOLOGIC FRACTURES
Favorite
P 172
COMPARISON OF CELL SEGMENTATION METHODS IN SOFT TISSUE SARCOMA (STS) SPATIAL PROTEOMIC DATASETS
Favorite
P 305
COMPARISON OF GOAL-DIRECTED VERSUS EMPIRICAL TRANSFUSION MANAGEMENT IN PATIENTS WITH SEVERE HEMORRHAGE DURING RETROPERITONEAL TUMOR SURGERY
Favorite
P 56
COMPARISON OF PATHOGENIC AND LIKELY PATHOGENIC VARIANTS DISTINCT FROM SPECIFIC DRIVERS IN DIFFERENT SARCOMA GROUPS
Favorite
P 373
COMPLETE RESPONSE TO FRONT-LINE PEXIDARTINIB IN SYMPTOMATIC TEMPOROMANDIBULAR JOINT TENOSYNOVIAL GIANT CELL TUMOR
Favorite
P 05
CONCORDANCE OF GENOMIC ALTERATIONS WITH CIRCULATING TUMOR DNA: INITIAL FINDINGS FROM A PILOT STUDY
Favorite
P 03
CONGRUENCE OF CIRCULATING TUMOR DNA & RADIOGRAPHIC RESPONSE IN BONE AND SOFT TISSUE SARCOMA
Favorite
P 147
CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA; IS ENCHONDROMA THE PRECURSOR LESION?
Favorite
P 72
COUNTY-LEVEL ASSOCIATIONS BETWEEN AIRBORNE TOXICANT EMISSIONS AND EWING SARCOMA DIAGNOSIS IN THE UNITED STATES
Favorite
P 292
CRANIOVERTEBRAL EWINGS SARCOMA WITH MENINGEAL INFILTRATION - A CLINICAL OUTCOME ANALYSIS
Favorite
P 293
CRYOABLATION FOR EXTRA-ABDOMINAL DESMOID TUMORS: A RETROSPECTIVE STUDY OF RADIOLOGIC AND CLINICAL OUTCOMES
Favorite
P 246
CTLA4 PATHWAY ACTIVATION IN RADIATION-INDUCED ANGIOSARCOMA: A TRANSCRIPTOMIC RATIONALE FOR IMMUNE CHECKPOINT BLOCKADE
Favorite
D
P 177
DEEP LEARNING AND DIMENSIONALITY REDUCTION FOR SARCOMA SUBTYPING
Favorite
P 176
DEEP LEARNING MODEL FOR DIFFERENTIATING BETWEEN NEOPLASTIC PATHOLOGIC FRACTURE AND NONPATHOLOGIC FRACTURE FROM PLAIN HIP RADIOGRAPHS
Favorite
P 23
DEFINING THE NONENZYMATIC FUNCTIONS OF LSD1 IN EWING SARCOMA
Favorite
P 110
DEFINITIVE RADIATION THERAPY IN "OPERABLE" EWING SARCOMA OF THE EXTREMITIES AND PELVIS
Favorite
P 114
DENOSUMAB THERAPY AND MIRELS ADJUSTED ODDS OF PATHOLOGIC FRACTURE OR PROPHYLACTIC STABILIZATION IN APPENDICULAR SKELETAL METASTASES
Favorite
P 263
DESCRIBING THE CHARACTERISTICS AND TREATMENT OF SYNOVIAL SARCOMA IN THE RECURRENT SETTING
Favorite
P 356
DESMOID TUMORS: A RETROSPECTIVE ANALYSIS FROM A REFERRAL CENTER
Favorite
P 229
DETERMINANTS OF DIAGNOSTIC INTERVAL IN EPITHELIOID HEMANGIOENDOTHELIOMA: A LINEAR AND QUANTILE REGRESSION ANALYSIS OF PATIENT-REPORTED DATA FROM THE SPAGN GLOBAL SARCOMA DIAGNOSIS PATHWAY SURVEY
Favorite
P 26
DEVELOPING AN ORTHOTOPIC MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Favorite
P 173
DEVELOPMENT AND EXTERNAL VALIDATION OF A MACHINE LEARNING ALGORITHM TO PREDICT OVERALL SURVIVAL IN PATIENTS WITH PELVIC OR APPENDICULAR LIPOSARCOMA
Favorite
P 357
DEVELOPMENT OF AN ALGORITHM TO IDENTIFY PATIENTS (PT) WITH DESMOID TUMORS (DT) IN A UNITED STATES (US) CLAIMS DATASET
Favorite
P 119
DEVELOPMENT OF AN EXTINCTION THERAPY APPROACH FOR OSTEOSARCOMA USING ECO-EVOLUTIONARY PRINCIPLES
Favorite
P 237
DEVELOPMENT OF EPHA2 CAR T CELL THERAPY FOR OSTEOSARCOMA
Favorite
P 455
DEVELOPMENT OF PATIENT-CENTERED INFORMATION MATERIAL ON RADIATION-INDUCED SARCOMA: QUALITATIVE RESULTS FROM FOCUS GROUPS OF THE TETRIS-PROJECT
Favorite
P 197
DIFFERENTIAL EFFECTS OF ANAGRELIDE IN GASTROINTESTINAL STROMAL TUMORS (GIST) IN VITRO
Favorite
P 392
DIFFERENTIATION OF MYXOMA AND MYXOID LIPOSARCOMA BASED ON RADIOMICS PHENOTYPES
Favorite
P 82
DISPARITIES IN OSTEOSARCOMA BY SOCIOECONOMIC STATUS
Favorite
P 200
DISSECTING INTRATUMORAL HETEROGENEITY IN GIST USING SPATIAL TRANSCRIPTOMICS
Favorite
P 37
DISSECTING THE TUMOR MICROENVIRONMENT OF UTERINE LEIOMYOSARCOMAS FOR TARGETED DRUG PREDICTIONS
Favorite
P 108
DISTANCE WEIGHTED MATCHING IN THE QUANTIFICATION OF EXCESS MORBIDITY IN EXTERNAL HEMIPELVECTOMY AND HIP DISARTICULATION
Favorite
P 374
DISTINCT PATTERNS OF METASTATIC SPREAD IN LEIOMYOSARCOMA: A COMPARATIVE ANALYSIS OF TRUNCAL AND EXTREMITY TUMOURS
Favorite
P 393
DISTINCT SECONDARY MUTATIONAL LANDSCAPES ARE ASSOCIATED WITH NAB2–STAT6 FUSION BREAKPOINTS IN SOLITARY FIBROUS TUMORS
Favorite
P 12
DNA REPLICATION STRESS AND DEFICIENT HOMOLOGOUS RECOMBINATION IN OSTEOSARCOMA RISK AND THERAPY
Favorite
P 233
DNG64-CAR-V+ REGIMEN SHOWS CLINICAL BENEFIT IN PATIENTS WITH ADVANCED CCNG1 ONCOGENE EXPRESSING SARCOMAS (NCT04091295)
Favorite
P 222
DO WE ALL SEE IT THE SAME: AN INTER-RATER RELIABILITY ANALYSIS OF THE MUSCULOSKELETAL TUMOR REGISTRY DATA ELEMENTS
Favorite
P 111
DOES DOSE MATTER? POSTOPERATIVE RADIATION DOSE AND OUTCOMES FOLLOWING FIXATION OF METASTATIC EXTREMITY BONE LESIONS
Favorite
P 375
DOES STAGED RESECTION WITH TEMPORIZING WOUND VACUUM INFLUENCE LOCAL RECURRENCE RISK? A MULTI-INSTITUTIONAL MATCHED COHORT ANALYSIS
Favorite
P 153
DOES THE QUANTITY OF DEDIFFERENTIATION MATTER IN THE CLINICAL OUTCOMES OF DEDIFFERENTIATED CHONDROSARCOMA? A 10-YEAR SINGLE TERTIARY INSTITUTIONAL EXPERIENCE OF A SERIES.
Favorite
P 234
DOXORUBICIN PLUS BOTENSILIMAB, A NEXT GENERATION CTLA4 INHIBITOR, WITH OR WITHOUT BALSTILIMAB, A PD1 INHIBITOR, IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS
Favorite
P 394
DUAL OR TRIMODALITY THERAPY VERSUS SURGERY ALONE IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST
Favorite
P 322
DYNAMIC PET/MRI REVEALS METABOLIC-DIFFUSION INTERACTIONS IN SUSPECTED SOFT TISSUE SARCOMAS
Favorite
E
P 04
EARLY ON-TREATMENT CIRCULATING TUMOR DNA DYNAMICS TO PREDICT RESPONSE IN PATIENTS WITH SARCOMA
Favorite
P 103
EARLY OUTCOMES OF BONE PROSTHESIS COMPOSITE FOR RECONSTRUCTION IN LOWER LIMB TUMORS. A SINGLE INSTITUTION STUDY
Favorite
P 358
EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R), IN HEALTHY PARTICIPANTS
Favorite
P 376
EFFECT OF ITRACONAZOLE (ITZ) AND RABEPRAZOLE (RBP) ON THE PHARMACOKINETICS (PK) OF VIMSELTINIB, AN ORAL INHIBITOR OF THE COLONY-STIMULATING FACTOR 1 RECEPTOR, IN HEALTHY PARTICIPANTS
Favorite
P 94
EFFECT OF POSTOPERATIVE PHYSICAL THERAPY ON FUNCTIONAL OUTCOMES FOLLOWING MUSCULOSKELETAL TUMOR RESECTION
Favorite
P 452
EFFECTIVENESS OF ERIBULIN FOR MYXOID PLEOMORPHIC LIPOSARCOMA: INSIGHTS FROM A PATIENT-DERIVED MODEL AND CLINICAL TRANSLATION IN A PATIENT WITH ADVANCED DISEASE
Favorite
P 32
EFFECTIVENESS OF LURBINECTEDIN PLUS IRINOTECAN IN PRECLINICAL MODEL OF DESMOPLASTIC SMALL ROUND CELL TUMOR
Favorite
P 417
EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Favorite
P 413
EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Favorite
P 152
EFFICACY OF PALLIATIVE CHEMOTHERAPY AND LOCAL TREATMENTS IN ADVANCED CHONDROSARCOMA: A SUBTYPE-SPECIFIC RETROSPECTIVE ANALYSIS
Favorite
P 191
EFFICACY OF SYSTEMIC PALLIATIVE THERAPIES IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) PREVIOUSLY TREATED WITH ADJUVANT IMATINIB - REAL-WORLD CLINICAL PRACTICE DATA
Favorite
P 464
EFFICACY OUTCOMES AMONG PATIENTS WITH ADVANCED EPITHELIOID SARCOMAS OF PROXIMAL-TYPE AND DISTAL-TYPE TREATED WITH TAZ: POST HOC ANALYSIS OF STUDY EZH-202
Favorite
P 422
EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Favorite
P 253
ELUCIDATING THE ROLE OF SIRT7 IN EWING SARCOMA
Favorite
P 254
EOSINOPHILIC FASCIITIS (EF) AS A COMPLICATION OF NATURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY IN A YOUNG ADULT WITH RECURRENT METASTATIC EWING SARCOMA
Favorite
P 459
EPIDEMIOLOGICAL TRENDS, TREATMENT PATTERNS, AND SURVIVAL DISPARITIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A SEER ANALYSIS, 2001-2020
Favorite
P 70
EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF CONTACTIN-4 EXPRESSION IN SOFT TISSUE SARCOMA
Favorite
P 69
EPIDEMIOLOGY AND POTENTIAL CLINICAL RELEVANCE OF TOP1 AND TOP2A TOPOISOMERASES EXPRESSION IN SOFT TISSUE SARCOMA
Favorite
P 395
ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Favorite
P 53
ESTABLISHMENT AND CHARACTERISATION OF LIPOSARCOMA-DERIVED CELLS AS RELEVANT PRE-CLINICAL MODELS FOR TARGET DISCOVERY
Favorite
P 09
ESTABLISHMENT AND CHARACTERIZATION OF 18 SARCOMA CELL LINES: UNRAVELING THE MOLECULAR MECHANISMS OF DOXORUBICIN RESISTANCE IN SARCOMA CELL LINES
Favorite
P 18
ESTABLISHMENT AND CHARACTERIZATION OF A NOVEL PRIMARY CELL LINE FROM A BONE METASTASIS OF OSTEOSARCOMA
Favorite
P 11
ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Favorite
P 136
ESTROGEN HAS A PROTECTIVE EFFECT ON CHONDROSARCOMA GROWTH IN VITRO AND IN VIVO
Favorite
P 262
EVALUATING FRONT-LINE THERAPY ACCORDANCE WITH CURRENT SYNOVIAL SARCOMA GUIDELINES
Favorite
P 165
EVALUATING LARGE LANGUAGE MODELS AS DECISION SUPPORT TOOLS IN MULTIDISCIPLINARY TUMOR BOARDS FOR GASTROINTESTINAL STROMAL TUMORS
Favorite
P 63
EVALUATING SURGICAL MARGINS IN SARCOMA RESECTION WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Favorite
P 14
EVALUATING THE COMBINATION OF DISULFIRAM AND ENZALUTAMIDE IN OSTEOSARCOMA
Favorite
P 396
EVALUATING THE SAFETY AND EFFICACY OF METRONOMIC GEMCITABINE, DOXORUBICIN, AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA: A PHASE 2 STUDY (NCT04535713)
Favorite
P 323
EVALUATION OF COSMIC MUTATIONAL SIGNATURES IN SOFT TISSUE SARCOMA
Favorite
P 359
EVALUATION OF PREOPERATIVE MYXOFIBROSARCOMA GROWTH AND SURGICAL MORBIDITY AFTER NEOADJUVANT RADIATION USING SEMI-AUTOMATED VOLUMETRIC ANALYSIS
Favorite
P 47
EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Favorite
P 21
EXAMINING THE THERAPEUTIC EFFECT OF TBL1/ β-CATENIN TARGETED COMBINATION THERAPIES ON METASTATIC OSTEOSARCOMA
Favorite
P 236
EXCEPTIONAL RESPONSE TO COMBINATION IMMUNOTHERAPY WITH YH001 AND ENVAFOLIMAB IN METASTATIC SARCOMA.
Favorite
P 432
EXPANSION OF A PHASE 1 STUDY OF SON-1010 (IL12-FHAB) ADDING TRABECTEDIN IN SOFT TISSUE SARCOMA: TRIAL IN PROGRESS
Favorite
P 198
EXPLOITING METABOLIC DYSREGULATION IN SUCCINATE DEHYDROGENASE-DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Favorite
P 60
EXPLORING METABOLIC REWIRING IN CHORDOMA
Favorite
P 397
EXPLORING REAL WORLD DATA OF RECURRENCE IN NON-METASTATIC MYXOFIBROSAROMA: AN UPDATED RETROSPECTIVE COHORT STUDY
Favorite
P 135
EXPLORING THE ROLE OF CLUSTER OF DIFFERENTIATION 44 IN CHONDROSARCOMA
Favorite
P 34
EXPRESSION OF ONCOFETAL ANTIGEN 5T4 IN SARCOMA SUBTYPES AND PRECLINICAL ACTIVITY OF TUB-030, A NOVEL 5T4-TARGETING ANTIBODY-DRUG CONJUGATE (ADC)
Favorite
P 463
EXTRANODAL FOLLICULAR DENDRITIC CELL SARCOMAS AND THEIR OLIGORECURRENCES: TRIUMPHS, TRIALS AND LESSONS LEARNT AT A SINGLE TERTIARY CANCER REFERRAL CENTRE, INDIA.
Favorite
P 17
EXTRASKELETAL OSTEOSARCOMA: MICRORNA PATTERNS PROVIDE INSIGHTS INTO SIMILARITIES AND CONTRASTS WITH OTHER SARCOMAS
Favorite
P 15
EZHIP: A NOVEL EPIGENETIC DRIVER OF OSTEOSARCOMA PATHOGENESIS
Favorite
F
P 102
FACTORS RELATED TO ASEPTIC LOOSENING IN ENDOPROSTHESIS RECONSTRUCTION OF THE PROXIMAL TIBIA
Favorite
P 01
FEASIBILITY OF A QUANTITATIVE METHYLATION-BASED CTDNA ASSAY IN PATIENTS WITH ADVANCED SARCOMAS
Favorite
P 270
FEASIBILITY OF FERTILITY PRESERVATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH SARCOMAS - A PROSPECTIVE COHORT STUDY WITH LONG-TERM FOLLOW-UP
Favorite
P 300
FEATURES AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL LEIYOMYOSARCOMA
Favorite
P 213
FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Favorite
P 214
FINANCIAL TOXICITY IN PATIENTS WITH A HISTORY OF EXTREMITY AND PELVIC SARCOMA TREATMENT
Favorite
P 109
FINITE ELEMENT ANALYSIS FOR FIXATION EVALUATION OF PATIENT-SPECIFIC ORTHOPEDIC IMPLANTS
Favorite
P 443
FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Favorite
P 228
FREQUENCY AND CLARITY OF SURGICAL GOALS FOR TUMOR RESECTION IN ADVANCED SARCOMA
Favorite
P 295
FROM HISTORICAL REFERENCE TO MODERN PRACTICE: WOUND COMPLICATION RATES IN SOFT TISSUE SARCOMA TREATED WITH RADIOTHERAPY ACROSS ERAS
Favorite
P 324
FULLY MATURE TERTIARY LYMHOID STRUCTURES AS PREDICTORS OF LOCAL RECURRENCE IN SOFT TISSUE SARCOMAS
Favorite
P 325
FUSION GENES IN SARCOMAS: DIAGNOSTIC APPROACHES AND EMERGING TARGETED THERAPIES
Favorite
G
P 446
GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Favorite
P 170
GEMSARC: AN AI BASED PREDICTIVE GENE SIGNATURE FOR GEMCITABINE EFFICACY IN ADVANCED SOFT-TISSUE SARCOMAS
Favorite
P 49
GENETIC INTERACTION BETWEEN SPRED3 AND SMARCB1 CAUSES EXPLOSIVE MULTIFOCAL MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Favorite
P 137
GENOMIC ALTERATIONS IN RARE CARTILAGINOUS TUMOR SYNDROMES ASSOCIATED WITH CHONDROSARCOMA DEVELOPMENT
Favorite
P 71
GERMLINE POLYMORPHISMS IN THE VEGF PATHWAY AS PROGNOSTIC BIOMARKERS IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: A STUDY BASED ON DATA FROM THE GEIS-33 PROTOCOL
Favorite
P 326
GERMLINE POT1 MUTATIONS IN ANGIOSARCOMA DIFFER FROM SOMATIC MUTATIONS
Favorite
P 377
GERMLINE RECQL4 VARIANT IN A PEDIATRIC PATIENT WITH EWING SARCOMA AND DESMOID FIBROMATOSIS
Favorite
P 158
GLOBAL INEQUITIES IN CHONDROSARCOMA CLINICAL TRIALS: A COMPREHENSIVE ANALYSIS ACROSS THREE DECADES
Favorite
P 225
GLOBAL REGISTRY OF SOLITARY FIBROUS TUMORS (SFT): INTEGRATING CLINICAL, MOLECULAR, AND ENVIRONMENTAL DATA- THE HOROWITZ SFT INITIATIVE (HSFTI)
Favorite
P 131
GLUCOSE TRANSPORTER 1 (GLUT1) INHIBITION DECREASES THE GROWTH AND PROLIFERATION OF CHONDROSARCOMA
Favorite
H
P 462
HDAC INHIBITORS AS POTENTIAL SFT THERAPIES
Favorite
P 444
HEALTH-RELATED QUALITY OF LIFE (HRQOL) CHALLENGES IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): ANALYSIS OF AN ULTRA-RARE SARCOMA GROUP
Favorite
P 211
HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Favorite
P 61
HER2 TARGETING IN CHORDOMA: PRECLINICAL INSIGHTS ON TRASTUZUMAB DERUXTECAN
Favorite
P 378
HIGH DOSE RADIATION THERAPY PROMOTES IMMUNE SUPPRESSIVE MACROPHAGE PHENOTYPES, WHEREAS LOW DOSE RADIATION THERAPY PROMOTES IMMUNOGENIC MACROPHAGE PHENOTYPES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Favorite
P 129
HIJACKED FUEL: GLYCOGEN-DRIVEN METABOLIC SHIFTS IN IDH1-MUTANT CHONDROSARCOMA
Favorite
I
P 25
IDENTIFICATION AND VALIDATION OF NON-GENETICALLY ENCODED VULNERABILITIES IN EWING SARCOMA
Favorite
P 288
IDENTIFICATION OF A DNA REPAIR INHIBITOR FOR THE COMBINATION WITH LURBINECTEDIN AND RADIOTHERAPY IN SARCOMA CELL LINES
Favorite
P 20
IDENTIFICATION OF A PROGNOSTIC GENE SIGNATURE FOR OSTEOSARCOMA RELAPSE BASED ON RESIDUAL TUMOR DISEASE AND ITS MICROENVIRONMENT
Favorite
P 242
IMMUNE PROFILING OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS REVEALS DISTINCT PROGNOSTIC SUBGROUPS
Favorite
P 139
IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Favorite
P 379
IMPACT OF EWSR1 GENE REARRANGEMENT TESTING ON DIAGNOSIS OF A WIDE RANGE OF SOLID TUMOURS
Favorite
P 195
IMPACT OF EXPERT-LED EDUCATION PROGRAMS ON HEALTH CARE PROVIDER (HCP) KNOWLEDGE OF GASTROINTESTINAL STROMAL TUMOR (GIST)
Favorite
P 279
IMPACT OF PREOPERATIVE 5-DAY HYPOFRACTIONATED RADIOTHERAPY (HFRT) FOR SOFT TISSUE SARCOMA (STS) ON BARRIERS TO TREATMENT AT A HIGH-VOLUME SARCOMA CENTER (HV-SC)
Favorite
P 206
IMPACT OF PROXIMITY TO HEALTH CENTER ON ADHERENCE TO NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES IN PATIENTS WITH SOFT TISSUE SARCOMAS
Favorite
P 308
IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Favorite
P 143
IMPACT OF SURGICAL MARGINS IN CHEST WALL CHONDROSARCOMAS: A CANSARCC STUDY
Favorite
P 118
IMPACT OF TYROSINE KINASE INHIBITOR THERAPY ON BONE PROGRESSION IN PATIENTS WITH DRIVER-MUTATED METASTATIC NON-SMALL CELL LUNG CANCER WITH DE NOVO BONE METASTASES
Favorite
P 249
IN VITRO EXPANSION OF TUMOR-INFILTRATING GAMMA-DELTA T-CELLS FROM PATIENTS WITH SOFT TISSUE SARCOMAS
Favorite
P 269
INCIDENCE OF MALIGNANCY IN BIOPSIED PEDIATRIC SOFT TISSUE MASSES
Favorite
P 157
INCOME IMPACTS OVERALL BUT NOT CAUSE-SPECIFIC SURVIVAL IN PATIENTS WITH CHONDROSARCOMA: A POPULATION BASED STUDY FROM THE SEER DATABASE
Favorite
P 231
INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Favorite
P 327
INITIAL TREATMENT MODALITY AND RECURRENCE IN NON-METASTATIC LEIOMYOSARCOMA: A RETROSPECTIVE COHORT STUDY
Favorite
P 328
INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Favorite
P 418
INTEGRATING SARCULATOR AND PET RESPONSE TO GUIDE NEOADJUVANT TREATMENT DECISIONS IN HIGH-RISK SOFT TISSUE SARCOMA
Favorite
P 134
INTEGRATIVE MICRORNA PROFILING IN CHONDROSARCOMA: TOWARD BIOMARKER DISCOVERY AND PROGNOSTIC SIGNATURE DEVELOPMENT
Favorite
P 93
INTERCALARY COMPRESSIVE OSSEOINTEGRATION OF DIAPHYSEAL TUMORS: A MULTI-INSTITUTIONAL CASE SERIES
Favorite
P 175
INTERPRETABLE DEEP LEARNING BASED CLASSIFICATION OF SARCOMA IMMUNE SUBTYPES FROM H&E SLIDES FOR IMMUNOTHERAPY STRATIFICATION
Favorite
P 286
INTERSTITIAL BRACHYTHERAPY FOR ORGAN AND FUNCTION PRESERVATION IN SOFT TISSUE SARCOMAS: LONG TERM OUTCOMES
Favorite
P 122
INTERVAL-COMPRESSED CHEMOTHERAPY FOR TREATMENT OF EWING SARCOMA IN ADULTS: A SINGLE INSTITUTION STUDY
Favorite
P 291
INTRA-ARTERIAL CHEMOTHERAPY WITH CONCOMITANT RADIATION THERAPY FOR UNRESECTABLE SARCOMA
Favorite
P 62
INTRAOPERATIVE BONE AND SOFT TISSUE TUMOR MARGIN IDENTIFICATION WITH FLUORESCENCE LIFETIME (FLT) IMAGING
Favorite
P 244
INTRATUMORAL TIGIT BLOCKADE AUGMENTS ANTI-TUMOR RESPONSES AND BYPASSES HYPERFUNCTIONALITY OF PERIPHERAL TIGIT+ NK CELLS IN MOUSE AND HUMAN MODELS OF BONE AND SOFT TISSUE SARCOMA
Favorite
P 238
INVESTIGATING HOW MACROPHAGES INFILTRATE THE TUMOUR MICROENVIRONMENT AND INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF STS
Favorite
P 130
INVESTIGATING LCP1-MEDIATED ONCOGENIC SIGNALING IN CHONDROSARCOMA METASTASIS
Favorite
P 65
INVESTIGATING MACROPHAGE POPULATIONS IN PRIMARY AND METASTATIC SARCOMA SAMPLES
Favorite
P 46
INVESTIGATING THE IMPACT OF SARCOMA FUSION PROTEINS ON EPIGENETIC AND DNA-DEPENDENT PROCESSES THROUGH INTERACTOME PROFILING
Favorite
P 258
INVESTIGATING THE ROLE OF ALVEOLAR PNEUMOCYTES IN THE LUNG MICROENVIRONMENT OF OSTEOSARCOMA METASTASES
Favorite
P 380
INVESTIGATING THE ROLE OF HISTONE DEACETYLASE-3 IN METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 398
INVESTIGATING THE SAFETY AND EFFICACY OF LURBINECTEDIN WITH IPILIMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA: LINNOVATE PHASE 1/2 STUDY (NCT05876715)
Favorite
P 133
INVESTIGATION OF COMBINING MDM2 INHIBITORS WITH DR5 AGONISTS FOR BONE SARCOMA TREATMENT
Favorite
P 431
INVOKE: A PHASE 1 STUDY OF OKN4395, A FIRST-IN-CLASS EP2/EP4/DP1 TRIPLE PROSTANOID RECEPTOR ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING SARCOMAS
Favorite
P 107
IS THERE A BETTER OPTION: INTRAMEDULLARY NAIL VERSUS PLATE OSTEOSYNTHESIS FOR PATHOLOGIC HUMERAL FRACTURES?
Favorite
P 232
IS THERE A ROLE FOR POSITRON EMISSION TOMOGRAPHY IN THE STAGING OF LANGERHANS CELL HISTIOCYTOSIS?
Favorite
P 128
ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Favorite
P 124
ISOLATED LIMB PERFUSION AS LIMB SALVAGING TREATMENT; A SINGLE CENTRE RETROSPECTIVE STUDY
Favorite
J
P 465
JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TODRIVE CIC-REARRANGED SARCOMAS
Favorite
K
P 381
KNOWLEDGE, ATTITUDES, AND BEHAVIOR OF HEALTHCARE PROVIDERS ENROLLED IN THE PEXIDARTINIB RISK MITIGATION AND EVALUATION PROGRAM
Favorite
L
P 472
LANDSCAPE OF ULTRA-RARE SARCOMAS: A NATIONWIDE STUDY FOR EPIDEMIOLOGY AND PROGNOSIS
Favorite
P 329
LAPAROSCOPY-ASSISTED PERCUTANEOUS CRYOABLATION FOR THE TREATMENT OF ABDOMINAL WALL DESMOID TUMORS
Favorite
P 167
LARGE LANGUAGE MODEL EXTRACTION OF STRUCTURED DATA FROM UNSTRUCTURED RADIATION ONCOLOGY NOTES: A PILOT STUDY
Favorite
P 166
LARGE LANGUAGE MODEL EXTRACTION OF STRUCTURED DATA IN UNSTRUCTURED SARCOMA PATHOLOGY NOTES: A PILOT STUDY
Favorite
P 399
LATE LOCAL RECURRENCE (>5YEARS) OF SOFT TISSUE SARCOMA OF THE EXTREMITIES AND TRUNK WALL: PREDICTIVE FACTORS AND ONCOLOGIC OUTCOMES
Favorite
P 330
LEIOMYOSARCOMA IN THE REAL WORLD: RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS AT A COMMUNITY ONCOLOGY CENTER IN SOUTH FLORIDA (MEMORIAL HEALTHCARE SYSTEM)
Favorite
P 168
LEVERAGING LARGE LANGUAGE MODELS FOR STRUCTURED INFORMATION EXTRACTION FROM EWING SARCOMA PATHOLOGY REPORTS
Favorite
P 99
LIMB SALVAGE FOR PROXIMAL TIBIA TUMORS: OUTCOMES OF ALLOGRAFT-PROSTHESIS COMPOSITE AND ENDOPROSTHETIC RECONSTRUCTION
Favorite
P 281
LOCAL CONTROL WITH MODERATELY HYPOFRACTIONATED DEFINITIVE RADIOTHERAPY DELIVERED WITH A SIMULTANEOUS INTEGRATED BOOST TECHNIQUE TO NON-EXTREMITY SOFT TISSUE AND BONE SARCOMAS
Favorite
P 282
LOCAL FAILURE ANALYSIS OF SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE ULTRA-HYPOFRACTIONATED RADIATION: UPDATE
Favorite
P 150
LOCAL RECURRENCE OF CHONDROSARCOMA: IMPACT ON SURVIVAL AND RECURRENCE AT AN INCREASED GRADE
Favorite
P 146
LOCALISED CHONDROSARCOMA PERIOPERATIVE TREATMENT: REAL-WORLD OUTCOMES AND CHALLENGES ACROSS HISTOLOGIC SUBTYPES
Favorite
P 164
LONG TERM OUTCOMES IN PATIENTS DIAGNOSED WITH SECONDARY CHONDROSARCOMA
Favorite
P 400
LONGITUDINAL EPIGENETIC AND TRANSCRIPTOMIC REMODELING ACROSS PRIMARY, IRRADIATED, AND LOCALLY RELAPSED SOFT TISSUE SARCOMAS
Favorite
P 207
LONG-TERM FOLLOW-UP AND LATE EFECTS MONITORING FOR UK BONE SARCOMA PATIENTS: A SERVICE MAPPING EXCERCISE
Favorite
P 401
LONG-TERM OUTCOMES OF IMATINIB-TREATED DERMATOFIBROSARCOMA PROTUBERANS: INSIGHTS FROM A SINGLE-INSTITUTION CASE SERIES
Favorite
P 402
LYMPH NODE METASTASES IN SOFT TISSUE SARCOMA: A DATABASE ANALYSIS
Favorite
M
P 241
MACROPHAGE INHIBITION ENHANCES PERIPHERAL CAR T CELL EXPANSION AND TUMOR CONTROL IN A PATIENT-DERIVED HUMANIZED MODEL OF AUTOLOGOUS CAR T CELL EFFICACY IN PEDIATRIC OSTEOSARCOMA (OS)
Favorite
P 428
MAINTENANCE PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS ACTIVE SURVEILLANCE FOR ADVANCED SOFT TISSUE SARCOMA PATIENTS WHO HAD CONTROLLED DISEASE AFTER STANDARD ANTHRACYCLINE-BASED TREATMENT (MELODY)
Favorite
P 331
MAINTENANCE THERAPY (M-TP) WITH DACARBAZINE (DTIC) AFTER FIRST-LINE ANTHRACYCLINE-BASED DOUBLET IN ADVANCED LEIOMYOSARCOMA (LMS) PATIENTS (PTS): OUTCOMES OF A CASE SERIES IN A SINGLE REFERRAL CENTER
Favorite
P 85
MAKING NEGATIVE MARGIN MUSCULOSKELETAL TUMOR SURGERY A VIRTUAL REALITY USING 3D SPECIMEN SCANNING
Favorite
P 304
MANAGEMENT OF RECURRENT RETROPERITONEAL SARCOMAS: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTER.
Favorite
P 332
MARGINAL EXCISION OF EXTREMITY DEDIFFERENTIATED LIPOSARCOMA WITHOUT RADIATION MAY BE SAFE IN SELECT PATIENTS
Favorite
P 260
MECHANISM AND EFFICACY OF ANTHRACYCLINE MEDIATED EPIGENETIC DISRUPTION IN BONE SARCOMAS.
Favorite
P 35
MECHANISTIC AND TRANSCRIPTOMIC ANALYSES REVEAL MUTATION-SPECIFIC THERAPEUTIC RESPONSES IN DESMOID TUMOR CELLS TREATED WITH SORAFENIB AND NIROGACESTAT
Favorite
P 403
MEDICAL MANAGEMENT OF TENOSYNOVIAL GIANT CELL TUMOR
Favorite
P 90
MEGAPROSTHESIS CONVERSION FROM FAILED OSTEOARTICULAR ALLOGRAFT VERSUS PRIMARY RECONSTRUCTION FOR DISTAL FEMUR AND PROXIMAL TIBIA TUMORS: A PROPENSITY MATCHED-PAIR ANALYSIS
Favorite
P 78
MENTAL HEALTH DISORDERS FOLLOWING PATHOLOGICAL FRACTURE: A RETROSPECTIVE COHORT STUDY
Favorite
P 333
METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.
Favorite
P 101
METAL ION MONITORING AFTER CUSTOM 3D-PRINTED IMPLANTS IN BONE TUMOR SURGERY: COMPARISON WITH MODULAR SYSTEMS AND EARLY OBSERVATIONS
Favorite
P 201
METASTATIC PATTERNS, TREATMENT MODALITIES, AND OVERALL SURVIVAL IN OLIGOMETASTATIC GIST: A SINGLE-CENTER RETROSPECTIVE STUDY
Favorite
P 382
METHOD FOR VOLUMETRIC ASSESMENT OF TUMOR RESPONSE FOLLOWING NEOADJUVANT RADIATION IN PRIMARY MYXOFIBROSARCOMA
Favorite
P 02
METHYLATION PROFILING AS A DIAGNOSTIC ADJUNCT FOR UNDIFFERENTIATED SARCOMAS: A REAL-WORLD EVALUATION
Favorite
P 203
MINIMALLY INVASIVE RESECTION OF MULTIFOCAL DUODENO-JEJUNAL GISTS IN NEUROFIBROMATOSIS TYPE 1
Favorite
P 212
MISINFORMATION IN SARCOMA CONTENT ON SOCIAL MEDIA PLATFORMS
Favorite
P 16
MITOCHONDRIAL GENETIC VARIATION ORCHESTRATES COPZ1 TRANSCRIPT HETEROGENEITY AND REVEALS TELOMERE-MEDIATED VULNERABILITIES IN OSTEOSARCOMA
Favorite
P 36
MODULATION OF THE SARCOMA MICROENVIRONMENT THROUGH β-ADRENERGIC BLOCKADE
Favorite
P 27
MOLECULAR CHARACTERIZATION OF RESPONSE TO NEOADJUVANT CHEMORADIATION IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMAS
Favorite
P 132
MOLECULAR LANDSCAPE AND CLINICAL HETEROGENEITY OF BRAZILIAN CHONDROSARCOMAS: INSIGHTS FROM IDH, TERT, AND GENOME-WIDE ANALYSIS
Favorite
P 45
MONITORING EWSR1 FUSIONS IN SARCOMA PATIENTS USING PERSONALIZED LIQUID BIOPSY ASSAYS
Favorite
P 360
MRI SURVEILLANCE PRACTICES AND RECURRENCE DETECTION IN EXTREMITY SOFT TISSUE SARCOMA: A RETROSPECTIVE STUDY
Favorite
P 334
MRI VOLUMETRIC AND MODIFIED CHOI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY DESMOID TUMORS TREATED WITH NIROGACESTAT OR SORAFENIB
Favorite
P 184
MTAP IN GASTROINTESTINAL STROMAL TUMOR (GIST): RATE OF MTAP LOSS AND CONCORDANCE BETWEEN GENOMIC SEQUENCING AND IMMUNOHISTOCHEMISTRY
Favorite
P 285
MULTICENTER STUDY OF SPATIALLY FRACTIONATED RADIOTHERAPY (LATTICE) FOR LARGE-VOLUME RADIORESISTANT SARCOMAS
Favorite
P 383
MULTIDISCIPLINARY TREATMENT OF INGUINOSCROTAL SARCOMAS: ANALYSIS OF 39 CASES TREATED BY SURGICAL APPROACH
Favorite
P 68
MULTI-OMIC INTRA- AND INTER-TUMOR HETEROGENEITY OF BENIGN SMOOTH MUSCLE TUMORS
Favorite
P 67
MULTIPLE MESENCHYMAL LINEAGES AS POTENTIAL CELL-OF-ORIGINS OF SMARCB1-DEFICIENT EPITHELIOID SARCOMA
Favorite
P 265
MULTI-SITE SINGLE CELL TRANSCRIPTOMICS REVEAL DISTINCT IMMUNE INFILTRATIVE PATTERNS IN DESMOPLASTIC SMALL ROUND CELL TUMOR
Favorite
P 303
MULTIVISCERAL RESECTIONS AND URINARY TRACT RECONSTRUCTION TECHNIQUES IN THE SURGERY OF RETROPERITONEAL SARCOMAS: A CASE SERIES.
Favorite
P 30
MYELOPEROXIDASE AS A POTENTIAL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMA
Favorite
N
P 179
NEOADJUVANT AVAPRITINIB IN PDGFRA-MUTANT GIST: NEAR COMPLETE PATHOLOGICAL RESPONSES AT THE COST OF HIGH ADVERSE EVENT RATES
Favorite
P 278
NEOADJUVANT HYPOFRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY IN EXTREMITY SOFT TISSUE SARCOMAS
Favorite
P 240
NEW INSIGHTS FROM SPATIOTEMPORALLY DEFINED TUMOR INDUCTIONS IN A NOVEL MOUSE MODEL OF SYNOVIAL SARCOMA
Favorite
P 275
NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT (AYA) SARCOMAS: CLINICAL IMPACT, DIAGNOSTIC UTILITY, AND IMPLICATIONS
Favorite
P 252
NUCLEAR AND GENOMIC ORGANIZATION OF CHEMOTHERAPY RESISTANT RHABDOMYOSARCOMA CELLS
Favorite
O
P 123
OFF-LABEL DENOSUMAB IN LOCALLY AGGRESSIVE BENIGN BONE TUMORS OTHER THAN GIANT CELL TUMOR OF BONE.
Favorite
P 470
OFF-LABEL TREATMENT AND ULTRARARE SARCOMAS - SINGLE INSTITUTION REPORT
Favorite
P 192
OPTIMAL DOSING SCHEDULE OF SUNITINIB BASED ON PLATELET COUNT IN AN OLDER PATIENT WITH GASTROINTESTINAL STROMAL TUMOR
Favorite
P 250
OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Favorite
P 450
OUTCOMES IN CLEAR CELL SARCOMA: UPDATED INSIGHTS FROM ELECTRONIC HEALTH RECORDS IN A PATIENT-LED REGISTRY
Favorite
P 456
OUTCOMES OF FIRST-LINE CHEMOTHERAPY IN ADVANCED ADULT-TYPE RHABDOMYOSARCOMAS: POOLED ANALYSIS OF CLINICAL TRIALS FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP
Favorite
P 223
OUTCOMES OF GERIATRIC PATIENTS WITH DE NOVO SARCOMA AND LUNG METASTASES: ROLE OF TUMOR CHARACTERISTICS AND TREATMENT STRATEGY
Favorite
P 460
OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Favorite
P 83
OUTCOMES OF MULTIMODAL PERIOPERATIVE TREATMENT IN OSTEOSARCOMAS OF THE JAW
Favorite
P 404
OUTCOMES OF NEOADJUVANT THERAPY IN ANGIOSARCOMA PATIENTS: A KAPLAN-MEIER-RECONSTRUCTED INDIVIDUAL PATIENT-LEVEL META-ANALYSIS
Favorite
P 453
OUTCOMES OF PLEOMORPHIC LIPOSARCOMA PATIENTS FOLLOWING MULTI-DISCIPLINARY MANAGEMENT WITHIN A TERTIARY CANCER CENTER
Favorite
P 335
OUTCOMES OF TALIMOGENE LAHERPAREPVEC IN SOFT TISSUE SARCOMA
Favorite
P 448
OVERCOMING CHALLENGES IN ULTRA-RARE SARCOMAS: A CENTRALIZED BIOBANK FOR EPITHELIOID HEMANGIOENDOTHELIOMA AS A RESOURCE TO ACCELERATE DISCOVERY
Favorite
P 43
OVERCOMING PROMISCUOUS TUMOR FORMATION: A CONTROLLED GENETICALLY ENGINEERED MOUSE MODEL OF CIC::DUX4 SARCOMA
Favorite
P 51
OVEREXPRESSION OF GLI2 IN DEDIFFERENTIATED LIPOSARCOMA TUMORS INDUCES MICROENVIRONMENT REMODELING
Favorite
P
P 447
PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Favorite
P 283
PALLIATIVE LATTICE RADIATION THERAPY IN SOFT TISSUE SARCOMA VERSUS CARCINOMA AND MELANOMA: OUTCOME COMPARISON
Favorite
P 405
PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Favorite
P 224
PAN-SARCOMA DATABASE (PSDB): AN UPDATE ON MIAMI'S COLLABORATIVE MULTI-USER DATA PIPELINE OF SARCOMA DATA USING REDCAP AND R CODING
Favorite
P 89
PATELLAR HEIGHT AND ITS INFLUENCE ON FUNCTIONAL OUTCOMES FOR MEGAPROSTHESES AROUND THE KNEE PERFORMED FOR ONCOLOGICAL INDICATIONS
Favorite
P 466
PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Favorite
P 145
PATHOLOGIC FRACTURE IN CHONDROSARCOMA OF LONG BONES: A RETROSPECTIVE COHORT STUDY
Favorite
P 217
PATIENT QUESTIONNAIRE EXPLORING THE PRE-SARCOMA DIAGNOSIS CHARACTERISTICS OF SARCOMA PATIENTS
Favorite
P 414
PATTERNS OF RELAPSE OF BORDERLINE AND MALIGNANT PHYLLODES TUMOUR- RESULTS FROM SARCOMA REFERENCE CENTRE (SRC)
Favorite
P 112
PEDIATRIC GIANT CELL TUMOR OF BONE
Favorite
P 384
PELVIC LOCATION PREDICTS WORSE OUTCOMES IN ALVEOLAR RHABDOMYOSARCOMA: UNDERUSE OF RADIOTHERAPY AND MISSED SURVIVAL BENEFIT
Favorite
P 98
PERCUTANEOUS STABILIZATION OF METASTATIC BONE LESIONS WITH A PHOTODYNAMIC INTRAMEDULLARY SYSTEM: EXPERIENCE FROM A 15-PATIENT CASE SERIES
Favorite
P 280
PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY (PULSAR) FOR ADULT AND PEDIATRIC SARCOMAS
Favorite
P 361
PEXIDARTINIB FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMORS: CLINICAL EXPERIENCE FROM FIVE CHINESE PATIENTS
Favorite
P 336
PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 5-YEAR RETROSPECTIVE HEPATIC SAFETY ASSESSMENT
Favorite
P 427
PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
Favorite
P 433
PHASE I DOSE ESCALATION TRIAL OF STX-001, AN LNP SELF-REPLICATING MRNA EXPRESSING IL-12, IN PATIENTS WITH REFRACTORY TUMORS INCLUDING SARCOMAS
Favorite
P 406
PILOT STUDY: CAN A MULTIPARAMETRIC MRI-DERIVED MODEL OUTPERFORM RECIST PREDICTING PATHOLOGY RESPONSE IN RHABDOMYOSARCOMA?
Favorite
P 407
PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Favorite
P 58
PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Favorite
P 337
POOLED ANALYSIS OF TRABECTEDIN EFFICACY IN MYXOID/ROUND CELL LIPOSARCOMA FROM THREE PROSPECTIVE CLINICAL TRIALS
Favorite
P 338
POORLY DIFFERENTIATED SYNOVIAL SARCOMA: A HISTOLOGIC CHALLENGE OF AN AGGRESSIVE VARIANT
Favorite
P 339
POSTERIOR APPROACH FOR RADICAL RESECTION OF SACROCOCCYGEAL CHORDOMA: A SURGICAL PERSPECTIVE FROM A TERTIARY REFERRAL CENTER
Favorite
P 48
PRECLINICAL ACTIVITY OF MEK INHIBITION IN COMBINATION WITH CHEMOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Favorite
P 40
PRECLINICAL EFFICACY OF A PH-SENSITIVE EXATECAN PEPTIDE-DRUG-CONJUGATE IN RHABDOMYOSARCOMA
Favorite
P 259
PRECLINICAL MODELING OF CHEMOTHERAPY RELEASE IDENTIFIES MITOCHONDRIAL ADAPTATIONS IN DOXORUBICIN TREATED OSTEOSARCOMA
Favorite
P 54
PRECLINICAL MODELS REVEALING MDM2-P53 INTERACTION AND DEPENDENCY FOR TUMOR CELL SURVIVAL IN WELL-DIFFERENTIATED (WD) AND DEDIFFERENTIATED (DD) LIPOSARCOMA (LPS).
Favorite
P 42
PRECLINICAL VALIDATION OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, AND EPIGENETIC SENSITIZATION STRATEGIES IN SOFT TISSUE SARCOMAS
Favorite
P 302
PREDICTORS AND OUTCOMES OF RECURRENT RETROPERITONEAL SARCOMA: A SINGLE-CENTER LATIN AMERICAN COHORT STUDY
Favorite
P 340
PREDICTORS OF LATE RECURRENCE AFTER SARCOMA SURGICAL RESECTION
Favorite
P 92
PRIMARY TUMOR SIZE AS AN INDEPENDENT PROGNOSTIC FACTOR IN OSTEOSARCOMA: PROPENSITY SCORE-MATCHED ANALYSIS DEMONSTRATES A CONTINUOUS DOSE-RESPONSE RELATIONSHIP
Favorite
P 385
PROGNOSTIC IMPACT OF PERIPHERAL BLOOD CELL RATIO VALUES IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: A REFERENCE CENTER EXPERIENCE.
Favorite
P 306
PROGNOSTIC NUTRITIONAL INDEX PREDICTS MAJOR POSTOPERATIVE COMPLICATIONS IN RETROPERITONEAL SARCOMA: RESULTS FROM THE LATAMSARC COHORT
Favorite
P 341
PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Favorite
P 342
PROGNOSTIC RELEVANCE OF TUMOR LOCATION IN MYXOID LIPOSARCOMA
Favorite
P 343
PROGRESSION FREE SURVIVAL OF IMMUNE CHECKPOINT INHIBITORS IN THE FIRST-LINE TREATMENT OF METASTATIC SARCOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS.
Favorite
P 419
PROSPECTIVE REAL-WORLD STUDY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SOLID TUMORS: INTERIM ANALYSIS OF ON-TRK
Favorite
P 296
PULMONARY CEMENT EMBOLISM ASSOCIATED WITH PERCUTANEOUS CEMENTOPLASTY FOR BONE METASTASIS: MECHANISMS AND PROTECTIVE FACTORS
Favorite
Q
P 221
QUALITATIVE ANALYSIS OF THE PERIOPERATIVE EXPERIENCE OF YOUNG ADULT PATIENTS UNDERGOING EXTREMITY SARCOMA SURGERY
Favorite
P 268
QUALITY OF LIFE OUTCOMES IN PEDIATRIC PATIENTS UNDERGOING SURGICAL INTERVENTION FOR LOWER EXTREMITY BONE SARCOMAS
Favorite
R
P 274
RACIAL DISPARITIES IN INCIDENCE AND MORTALITY OVER 20 YEARS AMONG AYA PATIENTS WITH SARCOMA IN THE US: A SEER DATABASE ANALYSIS
Favorite
P 276
RADIATION-INDUCED SARCOMA (RIS): CLINICAL SPECTRUM AND ONCOLOGIC OUTCOMES FROM A TERTIARY INDIAN SARCOMA CLINIC
Favorite
P 386
RADIO-GUIDED SURGERY FOR NONPALPABLE SOFT-TISSUE SARCOMAS
Favorite
P 273
RADIOMIC PREDICTORS OF SPONTANEOUS PNEUMOTHORAX DURING TYROSINE KINASE INHIBITOR THERAPY FOR LUNG METASTASES
Favorite
P 438
RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY VERSUS OBSERVATION IN NON-METASTATIC, HIGH-RISK SOFT TISSUE SARCOMAS (ACO-SARC TRIAL)
Favorite
P 06
RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Favorite
P 264
RARE CASE OF INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) IN NEWBORN
Favorite
P 121
REAL-WORLD EXPERIENCE OF CABOZANTINIB MONOTHERAPY IN RELAPSED OR REFRACTORY OSTEOSARCOMA AND EWING SARCOMA: A SINGLE-CENTRE AUSTRALIAN STUDY
Favorite
P 344
REAL-WORLD EXPERIENCE OF SORAFENIB IN DESMOID TUMOURS: A SINGLE-CENTRE AUSTRALIAN STUDY
Favorite
P 226
REAL-WORLD MANAGEMENT OF SYMPTOMATIC VS ASYMPTOMATIC TGCT FROM AN OBSERVATIONAL REGISTRY
Favorite
P 408
REAL-WORLD SINGLE-CENTER INSIGHTS INTO CT-DNA DYNAMICS ACROSS SOFT TISSUE SARCOMAS
Favorite
P 299
RECURRENCES AFTER PRIMARY RPS SURGERY IN A HIGH-VOLUME SARCOMA CENTER: A RETROSPECTIVE ANALYSIS ON 402 PATIENTS
Favorite
P 140
REFINING PRE-SURGICAL ASSESSMENT OF LONG-BONE CHONDROSARCOMA THROUGH THE RADIOLOGIC AGGRESSIVENESS SCORE
Favorite
P 106
REPAIR: A PRELIMINARY REPORT ON AN ONGOING MULTI-CENTER TRIAL FOR PATIENTS UNDERGOING SURGICAL STABILIZATION FOR METASTATIC BONE DISEASE OF THE FEMUR
Favorite
P 298
RESECTION OF PARA-RENAL INFERIOR VENA CAVA LEIOMYOSARCOMA WITH RIGHT NEPHRECTOMY AND LEFT RENAL VEIN LIGATION WITHOUT VENOUS RECONSTRUCTION.
Favorite
P 309
RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Favorite
P 219
RETROPERITONEAL SARCOMA: HEALTH SYSTEM BARRIERS AND THE RATIONALE FOR A SPECIALIZED SARCOMA UNIT
Favorite
P 301
RETROPERITONEAL SARCOMA: SINGLE CENTER EXPERIENCE IN LATIN AMERICA. DO WE HAVE DIFFERENT SARCOMAS WHEN COMPARED TO THE REST OF THE WORLD?
Favorite
P 409
RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Favorite
P 97
RISK FACTORS ASSOCIATED WITH AMPUTATION VERSUS CONTINUED LIMB SALVAGE IN LOWER EXTREMITY ENDOPROSTHETIC RECONSTRUCTION
Favorite
P 294
RISK FACTORS FOR RECURRENCE AND COMPLICATIONS OF CT-GUIDED RADIOFREQUENCY ABLATION FOR THE TREATMENT OF OSTEOID OSTEOMA: A MULTI-INSTITUTIONAL ANALYSIS.
Favorite
S
P 271
SAFETY AND EFFICACY OF CABOZANTINIB IN PEDIATRIC PATIENTS WITH MALIGNANT SOLID TUMORS (CAMEL TRIAL/NCCH2106): A SINGLE-CENTRE PHASE I TRIAL
Favorite
P 436
SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Favorite
P 345
SARCOMA BIOPSY COMPARISON BETWEEN REFERRAL CENTERS AND TREATING CENTERS: THE MUSCULOSKELETAL TUMOR REGISTRY (MSTR) EXPERIENCE
Favorite
P 209
SARCOMA PATIENT COMMUNITY DATA COLLABORATION TO ADVANCE RESEARCH
Favorite
P 19
SERUM EXOSOMES IDENTIFY AN ABERRANT PROTEOMIC SIGNATURE IN CANINE OSTEOSARCOMA PRECEDING METASTATIC PROGRESSION
Favorite
P 215
SHAPEHUB: A MULTICENTRE REAL-WORLD-TIME DATA PLATFORM WITH DIGITAL TWIN ENGINE FOR A LEARNING HEALTH SYSTEM IN SARCOMA
Favorite
P 362
SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Favorite
P 151
SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Favorite
P 313
SIGNIFICANCE OF LYMPH NODE PROCEDURES IN SOFT TISSUE SARCOMA PATIENTS
Favorite
P 22
SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA
Favorite
P 429
SINGLE-ARM, OPEN-LABEL PHASE II TRIAL OF XL092 (ZANZALINTINIB) IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: TRIAL IN PROGRESS
Favorite
P 126
SINGLE-CELL RNA SEQUENCING AND PROTEOMIC SPATIAL PROFILING REVEAL COMPLEX TUMOR MICROENVIRONMENT AND NOVEL IMMUNE INTERACTIONS IN CHONDROSARCOMA
Favorite
P 247
SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Favorite
P 115
SINGLE-CENTER EXPERIENCE WITH TYROSIN KINASA INHIBITORS IN ADVANCED BONE SARCOMA: EFFICACY AND SAFETY OUTCOMES
Favorite
P 289
SIX YEAR FOLLOW-UP ON CIVASHEET® USE FOR SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 251
SPATIAL MULTI-OMIC ANALYSIS OF RHABDOMYOSARCOMA IDENTIFIES THERAPEUTIC VULNERABILITIES
Favorite
P 307
STRATEGIES FOR DATA QUALITY IN TARPSWG RETROPERITONEAL SARCOMA REGISTRY (RESAR)
Favorite
P 57
STUDYING HYPOXIA-INDUCED METASTASIS IN GENETICALLY ENGINEERED MOUSE MODELS OF UPS
Favorite
P 410
SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Favorite
P 245
SUBTYPE SPECIFIC CHARACTERIZATION OF IMMUNE INFILTRATION IN SOFT TISSE SARCOMAS
Favorite
P 149
SURGICAL TEXTBOOK OUTCOMES IN PATIENTS DIAGNOSED WITH CHONDROSARCOMA
Favorite
P 346
SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
P 196
SURVEILLANCE STRATEGIES AND LONG-TERM OUTCOMES IN LOW-RISK GASTRIC GASTROINTESTINAL STROMAL TUMORS (GGISTS)
Favorite
P 347
SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS OF SOFT TISSUE SARCOMAS OF THE TRUNK AND EXTREMITIES TREATED BETWEEN 2010 AND 2015: EXPERIENCE OF THE BRAZILIAN NATIONAL CANCER INSTITUTE
Favorite
P 120
SURVIVAL OUTCOMES AND ROLE OF CHEMOTHERAPY IN PATIENTS OLDER THAN 40 YEARS WITH OSTEOSARCOMA (OLD-SARC STUDY).
Favorite
P 261
SUSTAINED RESPONSE WITH RIVOCERANIB AND DENOSUMAB IN RELASPED OSTEOSARCOMA
Favorite
P 348
SYNOVIAL SARCOMA INVOLVING NERVES: HIGH RATE OF MISIDENTIFICATION AS BENIGN TUMORS
Favorite
T
P 73
TARGETABLE GENE DEPENDENCIES IN EWING SARCOMA SUBTYPES
Favorite
P 59
TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Favorite
P 31
TARGETING CANCER STEM CELLS BY TYROSINE PEPTIDE ANALOGUE IN REFRACTORY SARCOMA
Favorite
P 125
TARGETING LCP1-MEDIATED METASTASIS IN CHONDROSARCOMA WITH OROXYLIN A
Favorite
P 257
TARGETING LEUCINE-RICH REPEAT-CONTAINING PROTEIN 15 (LRRC15): SOT106 ANTIBODY-DRUG CONJUGATE FOR SOFT TISSUE SARCOMA AND OSTEOSARCOMA TREATMENT
Favorite
P 266
TARGETING THE DNA DAMAGE RESPONSE TO ADVANCE PRECISION THERAPIES IN PAEDIATRIC SARCOMA
Favorite
P 445
TEADES PH1/2 STUDY WITH ODM-212: PRELIMINARY RESULTS IN EHE PATIENTS
Favorite
P 363
TEMPERATURE CHANGES IN THE IRRADIATED SKIN OF SOFT TISSUE SARCOMA PATIENTS
Favorite
P 190
TEMPORAL DECLINE IN PROGRESSION-FREE SURVIVAL, TIME ON MEDICATION, AND OVERALL SURVIVAL IN ADVANCED GASTROINTESTINAL STROMAL TUMOR
Favorite
P 74
TERTIARY LYMPHOID STRUCTURES PREDICT PROGNOSIS AND IMMUNE LANDSCAPE IN OSTEOSARCOMA: A MACHINE LEARNING-BASED TRANSCRIPTOMIC STUDY
Favorite
P 411
TFCP2 FUSION-POSITVE RHABDOMYOSARCOMAS: A REPORT OF 10 CASES AND A REVIEW OF THE LITERATURE
Favorite
P 349
THE COST OF SURVEILLANCE IN CALIFORNIA: MRI UTILIZATION IN RECURRENT EXTREMITY SOFT TISSUE SARCOMA
Favorite
P 181
THE DEVELOPMENT OF A NOVEL PDGFRA RESISTANCE MUTATION IN A RECURRENT KIT-MUTANT GASTROINTESTINAL STROMAL TUMOR (GIST)
Favorite
P 420
THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN THE MULTIPARAMETRIC MRI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Favorite
P 55
THE EFFECT OF STAT1 Y701 PHOSPHORYLATION ON GENE EXPRESSION IN UPS
Favorite
P 272
THE HAZARDS OF BIOPSY IN PEDIATRIC SOFT TISSUE SARCOMAS
Favorite
P 218
THE IMPACT OF BROADENED GENETIC COUNSELLING REFERRAL CRITERIA IN SARCOMA PATIENTS: A REFERENCE CENTRE'S EXPERIENCE
Favorite
P 41
THE IMPACT OF PAZOPANIB AND EXTREMITY RADIOTHERAPY ON TRANSAMINASES
Favorite
P 469
THE IMPACT OF PREOPERATIVE ANEMIA ON POSTOPERATIVE COMPLICATIONS AND SHORT-TERM PROGNOSIS IN RETROPERITONEAL TUMOR SURGERY PATIENTS.
Favorite
P 284
THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Favorite
P 220
THE IMPACT OF WOUND HEALING COMPLICATIONS ON PATIENT-REPORTED OUTCOMES FOLLOWING SOFT TISSUE SARCOMA SURGERY
Favorite
P 33
THE NOVEL TRANSCRIPTIONAL INHIBITORS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Favorite
P 350
THE PATTERN.ORG SARCOMA CONSORTIUM: BUILDING A MULTI-INSTITUTIONAL DATA RESOURCE FOR THE SARCOMA RESEARCH COMMUNITY
Favorite
P 267
THE RAF/MEK INHIBITOR VS-6766 SHOWS EFFICACY IN RAS-MUTANT PEDIATRIC PRECLINICAL XENOGRAFT MODELS- A REPORT FROM THE PEDIATRIC PRECLINICAL IN VIVO TESTING CONSORTIUM
Favorite
P 88
THE RAY CHALLENGE: HOW MANY RAY RESECTIONS CAN PATIENTS TOLERATE AND WHICH RAY RESECTIONS AFFECTS FUNCTIONAL OUTCOME THE MOST IN ORTHOPEDIC ONCOLOGY?
Favorite
P 144
THE RISK OF PATHOLOGICAL FRACTURES AFTER INTRALESIONAL CURETTAGE IN ATYPICAL CARTILAGINOUS TUMOURS: A RETROSPECTIVE COHORT STUDY
Favorite
P 100
THE ROLE OF CANCER TYPE IN THE DEVELOPMENT OF PERIPROSTHETIC JOINT INFECTION IN DISTAL FEMORAL REPLACEMENT
Favorite
P 277
THE ROLE OF RADIOTHERAPY IN THE MULTIDISCIPLINARY MANAGEMENT OF RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST: A REFERRAL CENTER EXPERIENCE
Favorite
P 351
THE ROLE OF SOCIOECONOMIC DISPARITIES ON SURVIVAL OUTCOMES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Favorite
P 256
THE SEAN KARL COHORT: A NATIONAL COLLABORATIVE SINGLE-CELL RNASEQ STUDY OF PAIRED PATIENT EWING SARCOMA SPECIMENS
Favorite
P 24
THE SIRTUIN SIRT5 SUPPORTS EWING SARCOMA SURVIVAL VIA REGULATION OF EWS-FLI1 STABILITY AND ACTIVITY
Favorite
P 187
THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Favorite
P 117
THERAPEUTIC POTENTIAL OF DOXORUBICIN AND DASATINIB COMBINATION IN OSTEOSARCOMA
Favorite
P 171
THREE-DIMENSIONAL DEEP LEARNING MODEL FOR PREDICTING PROXIMAL FEMORAL PATHOLOGIC FRACTURE USING OPPORTUNISTIC ABDOMINOPELVIC CT IN PATIENTS WITH ADVANCED CANCER: A PRELIMINARY REPORT
Favorite
P 352
TIME TOXICITY AND EFFECT OF CHEMOTHERAPY FOR PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE REAL-WORLD STUDY OF 244 PATIENTS
Favorite
P 210
TOWARDS INTERNATIONALIZATION OF THE CLINICAL RESEARCH COORDINATOR ROLE: THE FIRST DROP OF THE NIAGARA FALLS PROJECT
Favorite
P 13
TRANSCRIPTIONAL DIVERSITY AND NICHE REMODELING AT THE METASTATIC BOTTLENECK IN OSTEOSARCOMA
Favorite
P 208
TRANSLATION, CROSS CULTURAL ADAPTATION AND VALIDATION OF TESS IN REGIONAL INDIAN LANGUAGES WITH ~500 MILLION GLOBAL DIASPORA
Favorite
P 202
TRAVEL GRANT
Favorite
P 353
TREATMENT OF ADVANCED EPITHELIOID SARCOMA WITH COMBINATION TAZEMETOSTAT AND PEMBROLIZUMAB
Favorite
P 467
TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Favorite
P 451
TREATMENT OUTCOMES OF GEMCITABINE AND DOCETAXEL IN PATIENTS WITH CLEAR CELL SARCOMA (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES
Favorite
P 454
TREATMENT PATTERNS AND OUTCOMES IN RADIATION-INDUCED SARCOMA: FIRST RESULTS OF THE TETRIS-PROJECT - A MULTIMODAL RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTER
Favorite
P 387
TREATMENT PATTERNS AND PROGNOSTIC FACTORS IN LOCALISED SYNOVIAL SARCOMA: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA
Favorite
P 227
TREATMENT PATTERNS IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS: ADDRESSING COMMUNICATION IN A NEW THERAPEUTIC LANDSCAPE
Favorite
P 178
TREATMENT RESPONSE AND SURVIVAL OUTCOMES IN GASTROINTESTINAL STROMAL TUMORS FOLLOWING NEOADJUVANT THERAPY
Favorite
P 105
TREATMENT SUCCESS RATE AFTER SURGICAL MANAGEMENT OF PERIPROSTHETIC JOINT INFECTIONS IN ONCOLOGIC PROXIMAL TIBIA RECONSTRUCTION
Favorite
P 364
TRENDS IN SURGICAL MANAGEMENT OF DESMOID TUMOR IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Favorite
P 388
TRIAL IN PROGRESS: A PHASE 2 STUDY OF METRONOMIC TRABECTEDIN, GEMCITIBAINE, AND DACARBAZINE IN PREVIOUSLY TREATED ADVANCED SOFT TISSUE SARCOMA (NCT04535271)
Favorite
P 442
TRIAL IN PROGRESS: A SINGLE-ARM, OPEN-LABEL PHASE 4 TRIAL OF NIROGACESTAT IN ADULT PREMENOPAUSAL FEMALES WITH DESMOID TUMORS
Favorite
U
P 412
UNCOVERING HER2 OVEREXPRESSION IN SOFT TISSUE SARCOMAS (STS): INSIGHTS FROM THE CANCER GENOME ATLAS (TCGA)
Favorite
P 449
UNDERSTANDING GAPS IN KNOWLEDGE AND PATIENT-REPORTED PAIN IN EPITHELIOID HEMANGIOENDOTHELIOMA: RESULTS FROM A GLOBAL PATIENT REGISTRY
Favorite
P 354
UNEXPECTED RESPONSE TO ERIBULIN IN A REFRACTORY LEIOMYOSARCOMA PATIENT WITH HEREDITARY P53 MUTATION
Favorite
P 389
UNRESECTABLE AND METASTATIC DEDIFFERENTIATED LIPOSARCOMA (DDLPS): INSIGHTS FROM A MULTICENTER REAL-WORLD COHORT (RWC)
Favorite
P 194
UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Favorite
P 365
UROLOGICAL RECONSTRUCTION DURING RETROPERITONEAL AND PELVIC SARCOMA SURGERY: EXPERIENCE FROM A HIGH-VOLUME SARCOMA CENTER
Favorite
P 390
USE OF DERMAL TEMPLATE FOR NERVE PROTECTION IN LIMB-SPARING SURGERY FOR SOFT TISSUE SARCOMAS: PRELIMINARY EXPERIENCE FROM INSTITUT BERGONIE
Favorite
P 182
USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES OF PDGFRA EXON 18-MUTANT GIST
Favorite
P 80
UTILIZATION OF THE MUSCULOSKELETAL ONCOLOGY TUMOR REGISTRY AND TISSUE BANK (MOTOR) FOR THE ACCELERATION OF SARCOMA RESEARCH
Favorite
V
P 52
VALIDATION OF SYNGENEIC MURINE DEDIFFERENTIATED LIPOSARCOMA MODELS FOR PRECLINICAL EVALUATION OF THERAPEUTIC SENSITIVITY
Favorite
P 38
VALIDATION OF THE SIGNIOS SEVEN-GENE SIGNATURE FOR PREDICTING ANTI-PD-1 INHIBITOR EFFICACY IN SARCOMA
Favorite
P 216
VIRTUAL MULTIDISCIPLINARY MEETINGS IN THE CARE OF SARCOMA PATIENTS
Favorite
W
P 366
WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Favorite
Z
P 423
ZIFTOMENIB IN COMBINATION WITH IMATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) AFTER IMATINIB FAILURE: PHASE 1A/B STUDY OF SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY
Favorite
